90-Second Read: NIH Infectious Disease Chief Steps Down Amid Ebola and Hantavirus Response Concerns

Lawmakers raised concerns over leadership gaps during the Ebola outbreak in the Democratic Republic of Congo and ongoing Hantavirus monitoring efforts. Moderna ($MRNA), Federal infectious disease priorities and NIH funding decisions can impact vaccine and outbreak-response partnerships. Pfizer ($PFE), NIH and public health policy shifts may affect infectious disease research collaboration and funding.

The acting director of the National Institute of Allergy and Infectious Diseases resigned ahead of a Enter your email to receive free breaking news alerts and insights related to MRNA. NIH Director Jay Bhattacharya confirmed the institute is shifting priorities under the Trump administration as lawmakers raised concerns about staffing vacancies and delayed research funding. NIH Director Jay Bhattacharya said the administration is redirecting NIAID away from civilian biodefense and toward infectious diseases, allergy and immunology.

NIAID manages a budget exceeding $6.5 billion and played major roles in prior COVID-19 and Ebola responses. Gilead Sciences ($GILD), The company has exposure to antiviral and infectious disease treatment development tied to federal health initiatives. Jeffery Taubenberger stepped down as acting head of NIAID after serving since April 2025.